Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Selpercatinib Formulations
NCT05136404Phase 1Completed
- Sponsor
- Loxo Oncology
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selpercatinib in RET-altered solid tumors, Medullary Thyroid Cancer (MTC) and RET Fusion-Positive Thyroid Cancer (3 arms), sponsored by Loxo Oncology. Primary endpoints: Maximum Concentration of Selpercatinib at Day 15, Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity at Day 15 and 2 more. Started Dec 2021; status: completed.
02
Drugs
selpercatinib
03
Conditions
RET-altered solid tumorsMedullary Thyroid Cancer (MTC)RET Fusion-Positive Thyroid Cancer
Beyond the preview
Go deeper on NCT05136404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136404.